Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIRRHOUS FLOT/DOS
jRCTs031230231Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, levoleucovorin, oxaliplatin, docetaxel and tegafur in gastric adenocarcinoma (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jul 2023; status: active, not recruiting.
02
Drugs
fluorouracillevoleucovorinoxaliplatindocetaxeltegafur
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on jRCTs031230231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230231.